[A25-47] Lisocabtagene maraleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
Last updated 08.07.2025
Project no.:
A25-47
Commission:
Commission awarded on 11.04.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Cancer
| Project no. | Title | Status |
|---|---|---|
| A22-90 | Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-48 | Lisocabtagene maraleucel (DLBCL, HGBCL, PMBCL and FL3B, each after one prior therapy) – Benefit assessment according to §35a Social Code Book V | Commission completed |